期刊文献+

3-羰基-4-氮杂-△^5-雄甾烯-17-肟衍生物的合成及其抑制5α-还原酶活性研究 被引量:5

Synthesis and 5α-Reductase Inhibition Activity Evaluation of 3-Keto-4-aza-△^5-androstene-17-oximido Derivatives
原文传递
导出
摘要 以雄甾-4-烯-3,17-二酮(AD)为起始原料,合成了14个甾体17位肟醚和肟酯类新化合物.所合成的化合物结构均经过MS,1HNMR谱确证,并对所合成的化合物进行了老鼠5α-还原酶抑制生物活性初步评价.结果表明:受试化合物均有一定的5α-还原酶抑制活性,其中化合物5a,5c,5d有较高的5α-还原酶抑制活性,与参比药物Espristeride相当. Fourteen new 4-aza-△^5-androstene-17-oximido-ether and oximido-ester compounds were synthesized using androst-4-ene-3,17-dione (AD) as starting material. The structures of all the intermediates and final products were identified by MS and NMR. The product compounds were evaluated for their inhibition rate to rat liver microsomal 5α-reductase and the results show that all of the compounds exhibited 5α-reductase inhibition activity to some degree. Among them, compounds 5a, 5c and 5d showed the highest biological activity, which appeared to be at the same level of the contrasting drug Espristeride.
出处 《化学学报》 SCIE CAS CSCD 北大核心 2009年第13期1487-1491,共5页 Acta Chimica Sinica
关键词 4-氮杂-17-取代甾体 5Α-还原酶 抑制剂 合成 4-aza-17-substituted steroid 5α-reductase inhibitor synthesis
  • 相关文献

参考文献12

  • 1Russell,D.W.;Wilson,J.D.Annu.Rev.Biochem.1994,63,25.
  • 2Wilson,J.D.; Griffin,J.E.; Russel,D.W.Endocr.Rev.1993,14,577.
  • 3Metcalf,B.W.; Levy,M.A.,Holt,D.A.Trends Pharm.Sci.1989,10,491.
  • 4Abell,A.D.; Henderson,B.R.Curr.Med.Chem.1995,2,583.
  • 5Kenny,B.; Ballard,S.; Blagg,J.; Fox,D.J.Med.Chem.1997,40,1293.
  • 6Li,X.; Singh,S.M.; Labrie,E J.Med.Chem.1995,38,1158.
  • 7Ou,M.R.;Li,J.Q.Chin.J.Struct.Chem.2008,27,105.
  • 8Robinson,A.; DeLucca,I.; Drummond,S.Tetrahedron Lett.2003,44,4801.
  • 9Marks,L.S.; Partin,A.W.; Dorey,F.J.Urology 1999,53,574.
  • 10Rusrnusson,G.H.; Renoids,G.F.; Steinberg,N.G.J.Med.Chem.1986,29,2298.

同被引文献34

  • 1况刚,邹文俊,高小平.一种非同位素5α-还原酶抑制剂体外筛选模型的建立和应用[J].中药药理与临床,2005,21(4):61-64. 被引量:9
  • 2杨雄文,朱孔明,刘东志,周雪琴.3-羰基-4-氮杂-5-雄甾烯-17-肟衍生物的合成[J].化工学报,2006,57(4):898-901. 被引量:2
  • 3尤田耙,胡卫浩,潘显道.合成萘丁美酮的新方法[J].中国医药工业杂志,1996,27(8):339-340. 被引量:5
  • 4Khan N, Sultana S. Induction of renal oxidative stress and cell prolifera- tion response hy ferric nitrilotriaeetate(Fe-NTA): diminution by soy isoflavones[J]. Chem Biol Interact, 2004, 149( 1 ): 23 - 35.
  • 5Eli Lilly. Company LY 191704: type Isteroid 5a - reduetase inhibitor treat- ment of androgenic alopeeia [ J ]. Drugs Future, 1995, 20 (2) : 144.
  • 6Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age [ J ]. J Urol, 1984,132 ( 3 ): 474-479.
  • 7Uygur M C, Gut E, Arik AI, et al .Erectile dysfunction following treatments of benign prostatic hyperplasia: a prospecti,e study [ J ]. Andrologia, 1998,30: 5-10.
  • 8Eli Lilly, Company.LY 191704: type isteroid 5a-reductase inhibitor treatment of androgenic alopecia[ J ] .Drugs Future, 1995,20 ( 2): 144.
  • 9KHAN S A,ASIRIA A M,YUSUF M. Eur J Med Chem, 2009, 44: 2597.
  • 10KHAN S A,YUSUF M. Eur J Med Chem,2009, 44:2270.

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部